Holen Sie sich die Stockscreener-App
2.29
1.29%
-0.03
Handel nachbörslich:
2.34
0.05
+2.18%
Schlusskurs vom Vortag:
$2.32
Offen:
$2.34
24-Stunden-Volumen:
5.29M
Relative Volume:
1.19
Marktkapitalisierung:
$530.03M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-179.82M
KGV:
-1.7218
EPS:
-1.33
Netto-Cashflow:
$-159.16M
1W Leistung:
+1.33%
1M Leistung:
-13.91%
6M Leistung:
+16.24%
1J Leistung:
+74.81%
1-Tages-Spanne:
$2.28
$2.495
1-Wochen-Bereich:
$2.16
$2.495
52-Wochen-Spanne:
$0.76
$3.87
Gossamer Bio Inc Stock (GOSS) Company Profile
Firmenname
Gossamer Bio Inc
Sektor
Branche
Telefon
(858) 684-1300
Adresse
3115 MERRYFIELD ROW, SAN DIEGO, CA
Compare GOSS vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
2.29 | 536.98M | 0 | -179.82M | -159.16M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 12.04B | 3.95B | 3.34B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2025-09-10 | Hochstufung | UBS | Neutral → Buy |
| 2025-07-14 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-05 | Fortgesetzt | Wedbush | Outperform |
| 2023-07-27 | Herabstufung | UBS | Buy → Neutral |
| 2023-03-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-03-01 | Eingeleitet | Guggenheim | Neutral |
| 2022-12-07 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-12-07 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-12-07 | Herabstufung | SMBC Nikko | Outperform → Neutral |
| 2022-10-20 | Eingeleitet | Goldman | Buy |
| 2022-09-21 | Eingeleitet | JP Morgan | Neutral |
| 2022-09-19 | Eingeleitet | Wedbush | Outperform |
| 2022-04-18 | Eingeleitet | Raymond James | Outperform |
| 2022-04-06 | Eingeleitet | UBS | Buy |
| 2022-01-10 | Hochstufung | SMBC Nikko | Neutral → Outperform |
| 2021-11-09 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-09-21 | Fortgesetzt | Piper Sandler | Overweight |
| 2020-06-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-22 | Eingeleitet | Piper Sandler | Overweight |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2019-12-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-10-30 | Eingeleitet | Berenberg | Buy |
| 2019-03-05 | Eingeleitet | Barclays | Overweight |
| 2019-03-05 | Eingeleitet | BofA/Merrill | Buy |
| 2019-03-05 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-05 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Gossamer Bio Inc Aktie (GOSS) Neueste Nachrichten
Gossamer Bio’s Stock Whipsaws As Biotech Investors Weigh Risk, Cash Runway And Pipeline Hopes - AD HOC NEWS
Brokers Offer Predictions for Gossamer Bio FY2030 Earnings - MarketBeat
Big Money Bets On Gossamer Bio (GOSS) As Institutional Ownership Hits 81 Percent - AOL.com
MB Generational Wealth LLC Buys Shares of 1,414,824 Gossamer Bio, Inc. $GOSS - MarketBeat
Gossamer Bio (NASDAQ:GOSS) Trading Down 4.7%Here's What Happened - MarketBeat
Analysts Remain Bullish on Gossamer Bio (GOSS) Citing Undervaluation - Insider Monkey
11 Best Stocks Under $3 to Buy Right Now - Insider Monkey
Gossamer Bio Target of Unusually High Options Trading (NASDAQ:GOSS) - Defense World
Analysts Have Conflicting Sentiments on These Healthcare Companies: Minerva Neurosciences (NERV), Gossamer Bio (GOSS) and Merck & Company (MRK) - The Globe and Mail
Gossamer Bio, Inc. (GOSS): Biotech Stock With A Promising 283% Upside Potential - DirectorsTalk Interviews
Traders Buy High Volume of Gossamer Bio Put Options (NASDAQ:GOSS) - MarketBeat
Gossamer Bio (NASDAQ:GOSS) Shares Up 8.8%Should You Buy? - MarketBeat
Barclays Gives Gossamer Bio Overweight Rating and Bright Outlook - StocksToTrade
Gossamer Bio Sees Unusually Large Options Volume (NASDAQ:GOSS) - MarketBeat
Will Gossamer Bio Inc. stock outperform tech sector in 2025Layoff News & Safe Capital Investment Plans - mfd.ru
Gossamer Bio (NASDAQ:GOSS): The High-Stakes Gamble Drawing Big Bank Interest - AOL.com
Is Gossamer Bio Inc forming a breakout pattern2025 Price Action Summary & Weekly Sector Rotation Insights - baoquankhu1.vn
Gossamer Bio (NASDAQ:GOSS) Upgraded to "Strong-Buy" at Barclays - MarketBeat
Gossamer Bio (GOSS) Submits Mixed Securities Shelf Filing - GuruFocus
Barclays Initiates Coverage on Gossamer Bio With Overweight Rating, $9 Price Target - marketscreener.com
Barclays Initiates Coverage on Gossamer Bio (GOSS) with Overweig - GuruFocus
Institution Moves: Should I buy Gossamer Bio Inc stock nowTrade Signal Summary & Daily Stock Trend Watchlist - baoquankhu1.vn
Earnings Report: Is Gossamer Bio Inc a stock for growth or value investors2025 Performance Recap & Smart Swing Trading Alerts - baoquankhu1.vn
Gossamer Bio (NASDAQ:GOSS) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Gossamer Bio (NASDAQ:GOSS) Stock Price Down 5.7%Here's Why - MarketBeat
Cantor Fitzgerald reiterates Overweight rating on Gossamer Bio stock By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Buy rating on Gossamer Bio stock ahead of key trial By Investing.com - Investing.com India
Cantor Fitzgerald reiterates Overweight rating on Gossamer Bio stock - Investing.com
H.C. Wainwright reiterates Buy rating on Gossamer Bio stock ahead of key trial - Investing.com Nigeria
Gossamer Bio (NASDAQ:GOSS) Given Buy Rating at HC Wainwright - MarketBeat
GOSS: HC Wainwright & Co. Reiterates Buy Rating with $10 Price T - GuruFocus
With 63% institutional ownership, Gossamer Bio, Inc. (NASDAQ:GOSS) is a favorite amongst the big guns - Yahoo Finance
Gossamer Bio, Inc.'s (NASDAQ:GOSS) Popularity With Investors Under Threat As Stock Sinks 27% - simplywall.st
Gossamer Bio Inc Just Went Wild: Is This Tiny Biotech the Next Viral Moonshot or Total Trap? - AD HOC NEWS
Aug Spikes: How does Napco Security Technologies Inc score in quality rankingsTrade Volume Summary & Safe Capital Allocation Plans - baoquankhu1.vn
Pullback Watch: What are the risks of holding ProShares Trust ProShares Short MSCI Emerging MarketsWeekly Market Summary & Expert Approved Trade Ideas - baoquankhu1.vn
Gossamer Bio, Inc. (NASDAQ:GOSS) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
What is the fair value of Gossamer Bio Inc. stock nowTrade Exit Summary & Smart Investment Allocation Tips - Улправда
Is Gossamer Bio Inc. stock trading at a premium valuation2025 Winners & Losers & High Accuracy Investment Signals - Улправда
Gossamer Bio, Inc. (GOSS): Analyst Ratings Highlight a Significant 294% Upside for Biotech Investors - DirectorsTalk Interviews
How Gossamer Bio Inc. (4GB) stock reacts to stronger dollarTrade Analysis Report & AI Powered Market Entry Ideas - Улправда
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Biotech Gossamer Bio gives new hires a stake with long-term stock options - Stock Titan
Can Gossamer Bio Inc. stock hit record highs againJuly 2025 Macro Moves & Weekly Setup with High ROI Potential - Улправда
Gossamer Bio Sees Unusually High Options Volume (NASDAQ:GOSS) - Defense World
Finanzdaten der Gossamer Bio Inc-Aktie (GOSS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):